INCY Incyte Corp stock chart & analysis
Conviction 58HealthcareScan · Fri, Nov 6, 2026Incyte Corp (INCY) closed at $119.65 (+1.39%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 54, RS Rating 75, -9.7% from its 52-week high, +21.2% year to date. Sector: Healthcare · Services-Commercial Physical & Biological Research.
Financials as of Wed, Sep 30, 2026 · quarterly.
INCY technical analysis
Trend
INCY is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 0.1% above the 50-day ($119.62) and 10.4% above the 200-day ($108.43). ADX(14) at 15 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 54, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 75 puts its weighted 12-month performance ahead of about 75% of the US market.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $218.8M a day on average. ATR(14) is $4.10, 3.4% of price — its typical daily range.
Key levels
The chart pattern's support is $108.93 and its resistance $128.47. The 52-week range is $89.25 to $132.60; price is 9.7% below the high and 34.1% above the low. The VWAP anchored at the 52-week high is $120.63, above price.
Performance
INCY returned -0.6% (1 week), +6.2% (1 month), -1.5% (3 months), +21.4% (6 months), +13.2% (1 year), +21.2% (year to date).
About Incyte Corp
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Services-Commercial Physical & Biological Research · Listed 1993 · 2,844 employees
Congress activity
Disclosed STOCK Act trades in INCY · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Rob Bresnahan house · PA · traded 2025-05-15 | Sell | $1K–$15K | 2025-05-15 | 2025-05-31 |
Insider activity
SEC Form 4 transactions in INCY · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Tray Thomas Principal Accounting Officer · Common Stock · 2026-11-03 | Sell | 610 | $73K | 2026-11-03 | 2026-11-05 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-10-15 | Exercise | 839 | $60K | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-10-15 | Exercise | 423 | $26K | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-10-15 | Exercise | 455 | $28K | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-10-15 | Exercise | 925 | $59K | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-10-15 | Sell | 2.64K | $298K | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-10-15 | Exercise | 839 | — | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-10-15 | Exercise | 423 | — | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-10-15 | Exercise | 455 | — | 2026-10-15 | 2026-10-19 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-10-15 | Exercise | 925 | — | 2026-10-15 | 2026-10-19 |
SEC filings
EDGAR filings in INCY · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.